Online inquiry

IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6298MR)

This product GTTS-WQ6298MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), T cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6298MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3747MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ2108MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ9314MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ9815MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ735MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ13308MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ1491MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ10847MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M9346A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW